Abstract Several new methods have recently been developed for the treatment of malignant bone and softtissue tumors, and many of these targeted therapies have yielded promising initial results in clinical settings. As more sarcomas become amenable to effective moleculartargeting therapy, the need to evaluate the synergistic effects of combination therapies with anticancer drugs will grow. Other immunologic therapies have also been reported, such as exogenous cytokines, dendritic cell (DC) therapy and peptide vaccines. Cryoimmunology has shown promising results in some malignant tumors after cryosurgery and is expected to influence the next generation of tumor immunotherapy. In this report, we describe the induction of a systemic antitumor immune response following liquid nitrogen cryotreatment of a destructive murine osteosarcoma. Combining tumor cryotreatment with DCs to promote tumor-specific immune responses enhanced systemic immune responses and inhibited metastatic tumor growth. We also describe the induction of a systemic antitumor immune response following reconstruction for malignant bone tumors using frozen autografts treated with liquid nitrogen.
Introduction
Promising developments building upon standard cancer therapies, such as chemotherapy, radiotherapy and surgery, have dramatically improved patient survival for malignant bone and soft-tissue tumors. For example, osteosarcoma is the most common primary malignant bone tumor. A standard protocol of neo-adjuvant chemotherapy, combined with wide local excision, improves 5-year disease-free survival by 60-90% [1] [2] [3] [4] [5] [6] [7] . However, some patients are refractory to these treatments, and lung metastasis is often associated with a fatal outcome. Thus, a more effective systemic treatment is called for in these patients [8] .
Targeted therapies in bone and soft-tissue sarcomas
Molecular targeting therapy is one of many novel therapies developed in the 1990s that are effective against some carcinomas. However, these drugs have been embraced only slowly for clinical use in malignant bone and softtissue tumors in the clinic. Recently, there have been some reports of clinical trials utilizing molecular targeting therapy.
Sorafenib targets a tyrosine kinase inhibitor. Pacey et al. reported a Phase II trial of sorafenib (400 mg twice daily for 12 weeks or more) that included patients with advanced soft-tissue sarcoma. One patient achieved a partial response and three patients achieved minor responses, out of 26 patients [9] . The other Phase II study of sorafenib in patients with metastatic or recurrent sarcomas reported that five of 37 patients with angiosarcoma had a partial response (response rate 14%) [10] . As for antiangiogenic and immunomodulatory drugs, the most important regulator in angiogenesis is vascular endothelial growth factor (VEGF), which is targeted by several drugs, one such being the tyrosine kinase inhibitor semaxanib. Phase I data showed moderate drug-related toxicities. In 31 patients with soft-tissue sarcoma, one minor response and five stable diseases (SD) were demonstrated [11, 12] . Another anti-VEGF agent being tested is bevacizumab. A Phase II trial in combination with doxorubicin at 75 mg/m 2 in 17 patients with metastatic soft-tissue sarcoma was recently reported. Two partial responses (PR) were observed, while 11 patients had SD for four or more cycles. The 12% response rate was no greater than that observed for single-agent doxorubicin therapy. However, the 65% SD in patients suggests further study is warranted for these tumors [13] . Chemotherapy combined with bevacizumab is effective for soft-tissue sarcomas. Dramatic improvement was achieved with inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy [14] . Other combination therapies with sequential highdose (HD) ifosfamide, carboplatin and etoposide refractory to standard chemotherapy in patients with sarcoma and germ cell cancer (GCC) have been reported. One almost complete response in a patient with GCC, previously progressive with three preceding protocols, was observed. Six patients had a PR (sarcoma 4/13 patients; GCC 2/3 patients), and five patients achieved SD (sarcoma 5/13 patients) [15] . Of these combination therapies, the most extensively studied is the tyrosine kinase inhibitor pazopanib. In a Phase II study, pazopanib produced a progression rate arrest at 3 months sufficient to justify cohort expansion in patients with synovial sarcoma, leiomyosarcoma and a group of other tumors including those of vascular origin, but was relatively inactive against adipocytic tumors [16] .
Imatinib is a molecular-targeted drug that inhibits tyrosine kinase, as well as type III tyrosine kinase receptors, such as platelet-derived growth factor receptor (PDGFR), KIT, colony-stimulating factor 1 receptor (CSF-1R), and discoidin domain receptor (DDR). KIT-positive gastrointestinal stromal tumors (GISTs) and PDGFR-positive dermatofibrosarcoma protuberans (DFSP) have been reported to be responsive to imatinib treatment. A Phase II trial of imatinib in patients with relapsed or refractory KITpositive (excluding GISTs) or PDGFR-positive sarcomas was recently concluded. Twenty-two patients were evaluated for response. The response rate with a 600 mg/day dose of imatinib was 4.5% (0 complete responses, 1 partial response), however, this result did not indicate effectiveness of imatinib monotherapy in patients with relapsed or refractory KIT-positive (excluding GISTs) or PDGFRpositive sarcomas [17] . Neither long-lasting freedom from disease progression nor clinical benefit was observed for advanced chondrosarcoma in a Phase II trial [18] .
Immunologic treatment in bone and soft-tissue sarcomas
Advances in basic tumor immunology and preliminary evidence for clinical activity of immunotherapy in select settings have sustained optimism that immunotherapy will find an established place in cancer therapy. As for bone and soft-tissue sarcoma, there are currently a number of clinical trials of immunotherapy, and we highlight some positive data from selected studies in some detail below.
Cytokine therapy (interleukin-2: IL-2)
Luksch et al. have reported a clinical trial in osteosarcoma using IL-2, in which 18 children with localized osteosarcoma received four IL-2 courses (9 9 10 6 IU/ml/day 94), alternating with pre-and post-operative multiple chemotherapies. The results showed that intensive chemotherapies have no effect on IL-2-induced immune activation, and suggest a role for NK cells in the control of osteosarcoma [19] .
Dendritic cell immunotherapy
Dendritic cells (DCs) are effective professional antigenpresenting cells with the ability to prime both primary and secondary immune responses to tumor antigens. One Phase I clinical study using DCs against solid tumors in children, including osteosarcoma, has been reported. In this series, one patient with metastatic fibrosarcoma demonstrated a strong positive response without obvious toxic side effects [20] . The other clinical trial of DC vaccination was for chondrosarcoma. Immunotherapy with allogeneic DCs stimulated with tumor cell lysates was demonstrated to be feasible, safe and well tolerated. Unfortunately, this study did not observe any clinical or immune response following vaccination. CD4
? and CD8 ? T-regulatory cells could be responsible for the ineffectiveness of this particular immunotherapy [21] .
Tumor-specific peptide immunotherapy
Immunotherapy clinical trials are being conducted using a Wilms tumor (WT1) peptide for metastatic alveolar rhabdomyosarcoma. The patient received weekly intradermal injections of HLA-A*2404-restricted, 9-mer WT1 peptide against residual bone disease. After 3 months, her bone disease disappeared, concurrent with an increase in the frequency of WT1-specific cytotoxic T lymphocytes (CTLs) [22] . Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibodies have been employed in a clinical Phase II study coordinated by the Memorial Sloan-Kettering Cancer Center in New York. The purpose of this clinical trial is to determine whether immune therapy with anti-CTLA-4 antibody is effective in patients with advanced synovial sarcoma. A total of 17 patients will be recruited. In this study, the investigators are trying to induce an immune response against synovial sarcoma with anti-CTLA-4 antibody in recurrent disease [23, 24] .
Combination with immunotherapies
Mackall et al. reported a new immunotherapeutic regimen for recurrent or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma. Combinations of autologous T cells, influenza vaccinations, and DCs pulsed with peptides derived from tumor-specific translocation breakpoints and E7 with or without recombinant human interleukin-2 showed minimal toxicity and favorable survival (43% 5-year overall survival for immunotherapy patients compared with 15% for patients without immunotherapy) [25] .
Cryosurgery in carcinomas
The first documented uses of cryosurgery in the treatment of malignancy dates back to the 1840s using crushed ice and salt to treat superficial cancers [26] . However, it was not until the 1960s that this technology was advanced enough to be used in the treatment of primary and secondary malignancies [27] . Recently, cryosurgery using liquid nitrogen has been successfully used for the ablation of tumors in the liver [28] , prostate [29] and kidney [30] , and the palliative treatment of locally advanced breast cancers [31] .
Cryosurgery induces tumor cell death directly by causing damage to cell membranes and organelles and indirectly by causing vascular compromise through thrombosis of small vessels [32, 33] . With decreasing temperatures, the cells dehydrate and proteins are damaged because of high solute concentration, resulting in damage to the membranes and disruption of the enzymatic machinery of the cell. With faster cooling, ice crystals form inside the cells, damaging cell membranes and organelles by mechanical effects. With repeated freezing, thermal conductivity of tissue increases and spreads the damage. The indirect damage to cells occurs through vascular ischemia, resulting in cell death. Vessel wall damage can occur because of perivascular cellular hydration, resulting in vessel distension and mechanical injury, or from direct cell damage to endothelial cells lining the vessels. Both pathways ultimately lead to increased permeability, edema, and a coagulation cascade, giving rise to microthrombi in vessels and tissue ischemia. Reperfusion injury is also proposed to play a role in the cell damage [34] .
Cryosurgery in bone and soft-tissue sarcomas
There have been some reports of cryosurgery for bone tumors. Marcove et al. [35] reported the first cryosurgery for primary and metastatic bone tumors in 1968. They used cryosurgery as a therapy for benign bone tumors of aneurysmal bone cyst [36] , giant cell tumor [37] , chondroblastoma [38] , malignant bone tumor of chondrosarcoma [39] and osteogenic sarcoma [40] . Following tumor curettage, liquid nitrogen was poured into the bone cavity and then allowed to thaw. Freeze-thaw cycles were repeated 2-3 times to obtain maximum tissue necrosis. This method was difficult when treating tumor margins. Tsuchiya et al. developed a new cryosurgery method for reconstruction for malignant bone tumors using tumor-bearing autografts treated with liquid nitrogen. The operative technique consisted of en bloc excision of the tumor, removal of soft tissue, curettage of the tumor, drilling and preparation for internal fixation or prosthetic replacement before incubation for 20 min in liquid nitrogen, thawing at room temperature for 15 min, thawing in distilled water for 10 min, followed by internal fixation with an intramedullary nail, plate or composite use of prosthetic replacement [41] (Fig. 1) . A newly modified technique using pedicle frozen autografts to save the continuity of anatomic structures was reported recently [42] (Fig. 2) .
Cryoimmunology in carcinomas
Previous reports have suggested that the immune system is activated by cryosurgery. The immunologic effects of cryosurgery [43] were first documented by Shulman et al. [44] , who demonstrated the production of antibodies against rabbit male reproductive tissues after freezing. These antibodies, which reached a peak 7-10 days after cryoablation, were found to be tissue-and species-specific. Ablin et al. [45, 46] reported that spontaneous regression of metastases occurred after cryosurgery of a primary prostate tumor in clinical cases and coined the term ''cryoimmunotherapy''. They found enhancement of immune responses after repeated in situ freezing, which they explained was due to multiple inoculations with the same antigen. These anecdotal reports of regression of metastases in patients whose primary tumors were treated by cryosurgery further sparked interest in the immunostimulatory potential of cryoablation.
In animal models, cryosurgery of tumor tissue resulted in the rejection of tumor re-challenge and in inhibition of secondary and metastatic tumor growth. Neel et al. [47] showed increased resistance to tumor re-challenge in cryosurgically treated mice as compared to those mice whose tumors were amputated, ligated, or not treated. The mechanism of cryosurgery-induced immune responses was thought to be due to increased tumor-specific antibodies that arose after freezing. Bagley et al. [48] demonstrated that lymphocytes from cryosurgically treated animals were cytotoxic against the tumor cells the animals had been inoculated with, thus showing cell-mediated immunity to be at least partially responsible for the antitumor effects observed following cryosurgery. Misao et al. [49] further characterized the kinetics of cryoablation-induced antitumor immunity using metastasizing rat mammary tumor No. 1 in Spague-Dawley rats. They observed an initial decrease in antitumor immunity after cryosurgery, which later increased gradually to reach a peak at 10 weeks after cryosurgery. The initial dip was considered to be a result of the activation of suppressor cells due to cryosurgical stress or slow and steady absorption of antigens. Joosten et al. [50] demonstrated that freezing of one of the tumors was superior to excision in retarding the growth of the untreated tumor. They also demonstrated decreased metastatic growth of the melanoma cell line MV3 in mice treated by cryoablation as compared with surgical resection. Within 6 h of the procedure, mice whose tumors were frozen had higher interleukin-1 and tumor necrosis factor levels than mice whose tumors were excised. Sabel et al. [51] also examined the response triggered by cryosurgery in mammary adenocarcinoma (MT-901) in BALB/c mice. They found higher levels of the type 1 helper cytokines interleukin-2 and interferon-c (IFN-c) and higher tumor rejection rates in animals treated with cryoablation. Cryoablation also increased natural killer cell activity compared to surgery alone. The many promising results lead to questions about the mechanism(s) of cryoimmunology. Cryoablation of tumor tissue leads to coagulative necrosis of cells, which causes a cellular breakdown and release of intracellular contents and proinflammatory cytokines. In addition to cytokines, the release of heat-shock proteins, DNA, RNA, or the chromosomal protein high mobility group box chromosomal protein 1 serves as a stimulus for the innate immune response and attracts granulocytes, macrophages, and natural killer (NK) cells. These cells further release cytokines and chemokines.
Dendritic cells are critical professional antigen-presenting cells (APCs), crucially important in the capture, processing and presentation of tumor antigens to tumorspecific T cells [52] . Necrotic tumor debris contains endogenous ''danger signals,'' such as high mobility group box chromosomal protein 1, required for the activation and maturation of APCs. DCs reach the damaged tissue, take up tumor antigens in the context of inflammation and abundant cytokines, and undergo a change in phenotype with the upregulation of cell surface markers, such as costimulatory, adhesion and integrin molecules [53] . The activated APCs migrate to tumor-draining lymph nodes where they present tumor antigens on major histocompatibility complex molecules, as well as costimulatory signals, to tumor-specific T cells, inducing their activation. Activated effector CD4 T cells can attack major histocompatibility complex Class II ? tumors and provide help to a variety of antitumor effector cells, including CD8
? cytotoxic T cells, B cells and macrophages [34] .
Adjuvant therapy has also been considered in order to enhance immunity after cryosurgery. Urano et al. [54] reported that cryosurgery combined with administration of the polysaccharide Krestin increased cytokine production and cytotoxic activity. Lubaroff et al. [55] reported that cryosurgery combined with bacillus Calmette-Guerin (BCG) was capable of producing antitumor immunity that rejected on re-challenge. Udagawa et al. [56] recently reported that cryoablation combined with intratumoral administration of BCG cell-wall skeletons and DCs induced tumor-specific T cells and reduced metastases. Recently, there have been reports on the use of cryosurgery with injection of DCs as antigen-presenting cells. Machilenkin et al. [57] reported that intratumoral injections of DCs following cryosurgery led to local tumor-induced, tumor-specific cytotoxic T-lymphocyte responses as well as reduced lung metastasis and a prolonged survival rate in mouse models of lung carcinoma and melanoma. Den Brok et al. [53] reported that injection of immatured DCs following cryoablation induced DC maturation and antitumour immunity in a mouse melanoma cell model. Udagawa et al. [56] reported that intratumoral administration of dendritic cells stimulated with BCG cell-wall components, which matures and activates DCs, following cryoablation induced tumor-specific CD8
? T cells and increased the antitumor effect in a mouse colon cancer model. In a clinical study, Osada et al. reported that patients with unresectable liver tumors treated with cryosurgery displayed tumor necrosis not only in the treated areas, but also outside of the treated areas, and had increased serum IL-6, tumor necrosis factor-alpha, and Th1/Th2 ratio. However, patients with a localized effect who did not show reduced satellite lesions did not have increased cytokines and required another immune activation method [58] . On the other hand, all of cryosurgery didn't induce the immunological activation. Urano et al. reported that the volume of cryonecrotic tumor tissue had an effect of immune-activation. The large volume of cryonecrotic tumor tissue increased the number of metastatic nodules. This phenomenon was due to the large amount of cryonecrotic tumor antigen, so, called high zone tolerance [54] .
Cryoimmunology in bone and soft-tissue sarcomas
As in other malignant tumors, cryoimmunology for malignant bone and soft-tissue tumors has received a great deal of interest. We reported the possible induction of a systemic antitumor immune response induced by re-implantation of destroyed tumor tissue treated with liquid nitrogen in a murine osteosarcoma model [59] . Tissue from the tumor was frozen in liquid nitrogen, thawed in distilled water and re-implanted in the same animal. In addition, some mice received the immunologic response modifier OK-432. Re-implantation of tumor tissue after cryotreatment activated immune responses and inhibited metastatic tumor growth, and OK-432 synergistically enhanced the antitumor effect after treatment. Kawano et al. reported combining tumor cryotreatment with DC immunotherapy in order to promote tumor-specific immune responses. They investigated whether cryotreatment with DCs could enhance systemic immune responses and inhibit metastatic tumor growth in a same model. In order to evaluate the activation of antitumor immunity, they prepared six groups of C3H mice: excision only, DCs without reimplantation of the cryotreated primary tumor, reimplantation of the cryotreated primary tumor alone, DCs combined with reimplantation of the cryotreated primary tumor, DCs exposed to cryotreated tumor lysates without reimplantation of the cryotreated primary tumor, and DCs exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor. They then compared antitumor immunity between the groups. Mice that received DCs exposed to cryotreated tumor lysates with reimplantation of the cryotreated primary tumor group had high serum IFN-c, reduced pulmonary metastases, and increased numbers of CD8
? T lymphocytes in metastatic areas. Their conclusion was that combining tumor cryotreatment with DCs enhanced systemic immune responses and inhibited metastatic tumor growth [60] . We also evaluated the possible induction of a Table 1 The Immunologic reaction of patients undergoing reconstructions for malignant bone tumors using frozen autografts treated with liquid nitrogen Case Sex/age 
Conclusions
Cryoimmunology continues to evolve, and is impacted by further investigations into cryoimmunologic mechanisms and novel techniques to detect disease. The need for research is evident in several aspects of cryoimmunology, especially in better understanding how the immune system becomes activated, translating these discoveries to the clinic, and applying cryoimmunology to malignant bone and soft-tissue tumors. The benefits provided by cryoimmunology combined with adjunct chemotherapy require investigation. Preclinical work with experimental tumors shows cryoimmunologic responses, but, as yet, the means by which the responses can be reliably used in a clinical setting to treat human disease are still developing.
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